Join us on Monday, August 10 for the live webinar
5:00 PM – 6:00 PM ET
1 AMA PRA Category 1 Credit^TM

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.

A full library of presentation slides will also be made available for those who participate in this live webinar.

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Supporters
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Seattle Genetics and Verastem Inc.

Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma (HL) and T-Cell Lymphoma — Christopher R Flowers, MD, MS

• Efficacy and safety data with the use of ibrutinib alone or in combination with other systemic therapies for previously untreated MCL; ongoing and planned Phase III trials
• Clinical research data supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib in relapsed/refractory MCL; patient selection for use in routine practice and ongoing investigation
• Early activity, ongoing trials and current nonresearch role, if any, of venetoclax in relapsed/refractory MCL
• Role of brentuximab vedotin (BV) in combination with AVD (doxorubicin/vinblastine/dacarbazine) as first-line therapy for advanced classical HL; long-term follow-up from the Phase III ECHELON-1 trial
• Results from the Phase III KEYNOTE-204 trial evaluating pembrolizumab versus BV for patients with relapsed/refractory classical HL; implications for clinical practice
• Available activity and safety data with and ongoing evaluation of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, chemotherapy, BV) for patients with newly diagnosed or relapsed/refractory HL
• FDA approval of BV in combination with chemotherapy for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas; diagnostic and clinical implications

Diffuse Large B-Cell Lymphoma (DLBCL); Advances in CAR T-Cell Therapy for DLBCL and Other Lymphomas — Jeremy Abramson, MD

• Available efficacy and safety data leading to the FDA approval of polatuzumab vedotin in combination with bendamustine/rituximab for patients with relapsed/refractory DLBCL; ongoing Phase III POLARIX trial
• Longer-term follow-up from clinical trials evaluating the efficacy and safety of axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel in DLBCL
• Patient identification and appropriate referral for consideration of CAR T-cell therapy in DLBCL
• Key findings from the Phase I/II TRANSCEND CLL 004 trial assessing lisocabtagene maraleucel in relapsed/refractory chronic lymphocytic leukemia
• Recent FDA approval and optimal incorporation of brexucabtagene autoleucel into the management of relapsed/refractory MCL
• Rationale for the FDA RMAT (regenerative medicine advanced therapy) designation for tisagenlecleucel for patients with relapsed/refractory follicular lymphoma; ongoing evaluation and development plans
• Other recently approved (eg, selinexor) and promising investigational (eg, mosunetuzumab, tafasitamab) agents in DLBCL

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of Hodgkin and non-Hodgkin lymphomas.

Learning Objectives

• Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma (HL) and peripheral T-cell lymphoma, and use this information to enhance decision-making for patients.
• Appraise brentuximab vedotin as a component of first-line therapy for newly diagnosed classical HL, and assess the current and future effects on routine clinical practice.
• Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational chimeric antigen receptor-directed T-cell therapies to determine the current and/or potential utility of each in the management of diffuse large B-cell lymphoma, mantle cell lymphoma and other lymphomas.
• Appreciate the FDA approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone for previously untreated CD30-positive peripheral T-cell lymphoma, and counsel patients about the associated risks and benefits.
• Assess the ongoing clinical trials evaluating other novel investigational approaches for HL and non-Hodgkin lymphoma, and obtain consent from appropriate patients for study participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Abramson — Consulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, MorphoSys, Novartis; Contracted Research: Bristol-Myers Squibb Company, Seattle Genetics. Dr Flowers — Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas, Celgene Corporation, Eastern Cooperative Oncology Group, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc, V Foundation for Cancer Research.

RESEARCH TO PRACTICE STAFF MODERATOR, CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
— Planners, moderator, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Kite, A Gilead Company, Seattle Genetics and Verastem Inc.